David B. Radtke

Astringency Is a Trigeminal Sensation That Involves the Activation of G Protein-Coupled Signaling by Phenolic Compounds

Nicole Schöbel, David B. Radtke, Jessica Kyereme et al. · Chemical Senses · 2014 · 155 citations

Anesthetic Mechanism, Sensory Science, Sensory Systems +20

Regeneration of a model NOX storage/reduction catalyst using hydrocarbons as the reductant

Meshari Al‐Harbi, David B. Radtke, William S. Epling · Applied Catalysis B: Environmental · 2010 · 30 citations

Chemical Engineering, Catalytic Application, Engineering +5

A phase 1 study of LY3076226, a fibroblast growth factor receptor 3 (FGFR3) antibody–drug conjugate, in patients with advanced or metastatic cancer

Christian Kollmannsberger, Carolyn D. Britten, Anthony J. Olszanski et al. · Investigational New Drugs · 2021 · 26 citations

Antibody–drug Conjugate, Medicine, Immunology +9

Fixed-duration pirtobrutinib plus venetoclax with or without rituximab in relapsed/refractory CLL: the phase 1b BRUIN trial

Lindsey E. Roeker, Jennifer A. Woyach, Chan Y. Cheah et al. · Blood · 2024 · 19 citations · Full text

Structural Analysis of Peptide‐Acetaldehyde Adducts by Mass Spectrometry and Production of Antibodies Directed Against Nonreduced Protein‐Acetaldehyde Adducts

Reneé C. Lin, Jean B. Smith, David B. Radtke et al. · Alcoholism Clinical and Experimental Research · 1995 · 12 citations